ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1508	National Cancer Institute	Html	en	AIDS-Related Lymphoma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of AIDS-Related Lymphoma.	bone marrow involvement. 0.64582 San Francisco Department 0.640611 newly diagnosed AIDS 0.661519 classical HL 0.664649 AIDS-related PCNSL 0.673507 cART era 0.702538 systemic lymphoma 0.656424 Epstein-Barr virus 0.637436 2-year overall survival 0.64874 HIV-infected homosexual men 0.643658 worse median survival 0.6947 median overall survival 0.678448 non-Hodgkin lymphomas 0.64597 patients 0.884787 Burkitt lymphoma 0.731575 certain opportunistic infections 0.656652 AIDS-related lymphomas 0.747647 HIV-associated HL presents 0.728404 immunodeficiency virus type 0.664684 large cell/immunoblastic lymphoma 0.706838 active antiretroviral therapy 0.65426 additional epidemiologic studies 0.641093 AIDS-related lymphoma 0.689324 large B-cell lymphoma 0.712331	human immunodeficiency virus 0.98371 OS rate 0.662052 et al. 0.677948 antiretroviral therapy 0.808834 opportunistic infections 0.717427 AIDS-related CNS infections 0.686364 Hodgkin lymphoma 0.73104 non–HIV-associated HL 0.666192 noncleaved cell lymphoma 0.70352 lymphoma 0.790941 Clin Oncol 0.63995 classical Hodgkin lymphoma 0.712756 lymphocyte-depleted HL 0.665739 anal cancer 0.646441 bone marrow 0.855918 median survival time 0.884464 newly diagnosed HL 0.722202 immunodeficiency virus results 0.662299 primary effusion lymphoma 0.746053 nervous system lymphoma 0.644768 previously diagnosed AIDS 0.751325 immunoblastic non-Hodgkin lymphoma 0.707885 HIV infection 0.640421 cerebral toxoplasmosis 0.679755	CLICK HERE
1560	National Cancer Institute	Html	en	Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of bile duct cancer.	cancer treatment 0.353124 bile ducts 0.564994 bile duct cancer 0.93969 body 0.371618 Recurrent bile duct 0.466297 extrahepatic bile duct 0.483916 PDQ cancer information 0.368 resectable perihilar bile 0.374861 perihilar bile duct 0.569945 clinical trial search 0.384576 bile duct 0.961515 clinical trials 0.565197 nearby lymph nodes 0.369687 cancer information summary 0.357079 resectable bile duct 0.431592 bile duct cancers 0.440742 liver 0.42559 patients 0.355382 clinical trial 0.45121 distal extrahepatic bile 0.464256 radiation therapy 0.471059 small intestine 0.398038 intrahepatic bile duct 0.502288 treatment 0.464058 transhepatic biliary drainage 0.355933	NCI-supported cancer 0.356212 cancer cells 0.412313 bile duct wall 0.415716 stage bile duct 0.454009 metastatic perihilar bile 0.377513 common bile duct 0.446017 National Cancer Institute 0.386156 Stent placement 0.359539 metastatic bile duct 0.439918 new treatment 0.359129 common hepatic duct 0.40199 external radiation therapy 0.3932 carry bile 0.373127 procedure 0.357714 swollen bile ducts 0.401928 cystic duct 0.364061 cancer clinical trials 0.390707 duct cancer cells 0.3797 resectable intrahepatic bile 0.377924 tumor 0.353722 intrahepatic bile ducts 0.394408 internal radiation therapy 0.382915 metastatic intrahepatic bile 0.380622 information 0.370053	CLICK HERE
1576	National Cancer Institute	Html	en	Prostate Cancer Screening (PDQ®)–Patient Version	Expert-reviewed information summary about tests used to detect or screen for prostate cancer.	PDQ Screening 0.238955 prostate gland 0.262783 following PDQ summaries 0.255959 Cancer Information Service 0.234967 PDQ cancer information 0.447798 Prevention Editorial Board 0.248763 men 0.210517 National Cancer Institute 0.335949 clinical trials 0.389256 PDQ documents 0.200757 test result 0.223183 benign prostatic hyperplasia 0.273839 cancer information summary 0.326548 newly diagnosed prostate 0.284247 clinical trial 0.213023 new treatment 0.208327 breast cancer prevention 0.217981 early cancer detection 0.236129	Cancer screening trials 0.28054 test 0.242059 Cancer Care page 0.221557 PDQ database 0.205174 prostate cancer gene 0.339499 NCI’s PDQ 0.209119 prostate cancer screening 0.411947 PDQ summary 0.286479 cancer symptoms 0.211597 NCI PDQ cancer 0.287762 prostate cancer 0.971006 tests 0.264624 bigger prostate 0.262229 PSA test 0.20487 Prostate Cancer Prevention 0.350483 cancer information summaries 0.242796 comprehensive cancer information 0.243032 high PSA level 0.200418	CLICK HERE
1631	National Cancer Institute	Html	en	Merkel Cell Carcinoma Treatment (PDQ®)–Patient Version	Merkel cell carcinoma is a rare disease in which cancer cells form in Merkel cells in the skin and starts most often in areas of skin exposed to the sun. Find out about risk factors, symptoms, tests to diagnose, prognosis, staging, and treatment for Merkel cell carcinoma.	cancer treatment 0.369679 distant parts 0.362908 lymph node dissection 0.588951 body 0.395316 PDQ cancer information 0.408963 clinical trial search 0.383573 metastatic Merkel cell 0.359176 clinical trials 0.614596 nearby lymph nodes 0.400683 cancer information summary 0.387551 clinical trial 0.501642 Merkel cells 0.371884 tumor area 0.368378 patients 0.364556 lymph node biopsy 0.419179 sentinel lymph node 0.455835 radical lymph node 0.418343 Recurrent Merkel cell 0.378899 malignant tumor cells 0.373594 NCI PDQ cancer 0.361276 Treatment Option Overview 0.361132 lymph nodes 0.564493 radiation therapy 0.43011 Treatment Editorial Board 0.360626 general cancer information 0.354614	treatment 0.462922 wide local excision 0.414099 swollen lymph nodes 0.431138 NCI-supported cancer 0.355921 cancer cells 0.429285 Cancer Information Service 0.355025 treatment clinical trials 0.372695 National Cancer Institute 0.42114 Cell Carcinoma Treatment 0.359564 regional lymph node 0.418618 lymph vessels 0.377608 new treatment 0.401967 merkel cell carcinoma 0.969094 primary tumor 0.368519 cancer clinical trials 0.393874 stage 0.380167 cell lung cancer 0.358436 tumor 0.434689 comprehensive cancer information 0.354073 cancer 0.71533 information 0.409547 lymph ducts 0.372558 standard treatment 0.354595 physical exam 0.362972	CLICK HERE
1766	National Cancer Institute	Html	en	Accidents at Nuclear Power Plants and Cancer Risk	A fact sheet about cancer risks associated with accidents at nuclear power plants.	Atomic Radiation 0.316376 Radiation risks 0.325562 radiation exposures 0.328269 nuclear accident sites 0.293301 Radiation Research 0.323015 low levels 0.272065 nuclear power plant 0.97677 I-131 exposure 0.297263 radiation sickness 0.405841 high doses 0.352667 radiation emergencies 0.31438 Chernobyl nuclear power 0.302487 Additional radioactive isotopes 0.311741 dangerous radioactive isotopes 0.306851 cancer patients 0.299868 greatest cancer risks 0.294897 cancer risks 0.312758 radioactive materials 0.379547 radiation therapy 0.335122 unstable isotopes 0.274 Radiation Effects Research 0.350011 external radiation 0.312725 power plant disaster 0.278559 radioactive isotopes 0.53284 ionizing radiation 0.412892	health effects 0.355744 future nuclear accidents 0.300229 nuclear reactors 0.284713 power plant accident 0.397996 nuclear weapons explosions 0.282249 thyroid gland 0.292634 thyroid cancer 0.388789 radiation exposure 0.375545 power plant accidents 0.566854 Radiation Emergency Medical 0.344768 I-131 0.306486 radioactive exposure 0.273465 National Cancer Institute 0.340697 specific radioactive materials 0.295979 breast cancer risk 0.282358 Radiation Epidemiology Branch 0.341242 Chernobyl-related thyroid cancer 0.291023 radiation 0.697647 cancer risk 0.309268 et al 0.275755 medical x-ray machines 0.33168 cancer 0.423405 Chernobyl accident 0.42803 certain radioactive isotopes 0.3079	CLICK HERE
1863	National Cancer Institute	Html	es	Tratamiento de la leucemia de células pilosas (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de la leucemia de células pilosas.	cell leukemia treated 0.413444 cell leukemia patients 0.427269 long-term follow-up 0.427434 Rituximab with pentostatin 0.40359 Peaud PY 0.40245 hairy cell leukaemia 0.411122 initially with pentostatin 0.406363 Foucar MK 0.403895 leukemia patients treated 0.417121 leukemia following treatment 0.406508 células pilosas 0.473847 treated with rituximab 0.403745 Instituto Nacional 0.402568 cell leukemia following 0.408562 Else M 0.404329 with pentostatin 0.442439 or refractory hairy 0.403457 VH4-34+ hairy cell 0.404297 Natl Cancer Inst 0.402731 Federico M 0.402782 Leuk Lymphoma 0.424893 long term 0.40908 patients treated with 0.423309 Burian C 0.403658 Matutes E 0.403796	leukemia treated with 0.41301 patients with hairy 0.610395 following treatment with 0.408927 Italian Cooperative Group 0.40697 hairy-cell leukemia with 0.408245 relapsed or refractory 0.403586 National Cancer Institute 0.404377 after treatment with 0.408757 untreated patients with 0.407444 with poor prognosis 0.40323 with 2-CdA 0.403201 cell leukemia with 0.426877 treatment with 0.420376 hairy cell leukemia 0.998262 Clin Oncol 0.444146 treated with pentostatin 0.422653 leukemia with pentostatin 0.404444 leukemia after treatment 0.406381 Long term results 0.402405 treated with 0.429875 treated initially with 0.406289 previously untreated patients 0.40321 PDQ Sofocos 0.402915 cell leukemia after 0.412869	CLICK HERE
1994	National Cancer Institute	Html	es	Tratamiento del craneofaringioma infantil (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del craneofaringioma infantil	childhood-onset craniopharyngioma 0.555421 Winkfield KM 0.461372 Merchant TE 0.538632 Pediatric Patients with 0.460492 largo plazo 0.456579 brain tumors 0.465364 cystic craniopharyngiomas 0.546839 pediatric craniopharyngiomas with 0.478389 after childhood-onset craniopharyngioma 0.509117 calcificación quizás 0.453393 craneofaringioma infantil grupo 0.448145 past treatment modalities 0.44452 Instituto Nacional 0.469284 Proton beam therapy 0.44785 proton radiotherapy 0.445521 Radiat Oncol Biol 0.691179 Pediatric Brain Tumor 0.463199 Endocrinol Metab 0.525086 Gebhardt U 0.460882 central nervous system 0.452583 proton therapy 0.48171 tumor control 0.4621 Optimal treatment strategy 0.445937 radiation therapy 0.847388 Clin Endocrinol Metab 0.477641	following treatment 0.481728 subtotal quizás 0.449448 Neurosurg Focus 0.603105 Pediatric MATCH 0.494065 pediatric craniopharyngioma 0.961568 tumores quísticos recidivantes 0.450542 PDQ Descripción 0.449293 Pediatr Blood Cancer 0.611837 after radiation therapy 0.60095 With Craniopharyngioma That 0.51489 efectos tardíos 0.785518 PDQ Efectos tardíos 0.471103 tumor control with 0.459757 Neurosurgical treatment 0.478026 National Cancer Institute 0.453747 with proton radiotherapy 0.445448 tumor quizás 0.486067 PDQ Tratamiento 0.463786 treatment strategy 0.478645 long-term results 0.483149 Oncol Biol Phys 0.703438 Neurosurg Pediatr 0.66815 long-term gh therapy 0.447185 patients with craniopharyngioma 0.738686	CLICK HERE
3449	National Cancer Institute	Html	es	Prevención del cáncer de ano (PDQ®)–Versión para pacientes	Sumario de información revisada por expertos sobre factores que pueden influir en el riesgo de presentar cáncer de ano y sobre las investigaciones dirigidas a prevenir esta enfermedad.	preservativos protege 0.348482 siguientes factores 0.806347 suficientes estudios 0.342762 voluntarios sanos 0.341993 Physician Data Query 0.494379 fuerte factor 0.356186 Estados Unidos 0.640069 suficiente ejercicio 0.356939 cuello uterino 0.913633	prevención revisa 0.348763 PDQ Prevención 0.389253 largo plazo 0.344404 principal factor 0.355962 sexo anal 0.379093 National Cancer Institute 0.350168 siguientes riesgos 0.341101 siguientes prácticas 0.360133 Instituto Nacional 0.391026	CLICK HERE
16860	National Cancer Institute	Html	en	Transfer of a Grant	NIH prior approval is required for the transfer of a grant. Learn more about transferring a cancer research grant from one entity to another.	Acceptance 0.529837 activity 0.531251 transfer application 0.649492 new sponsoring organization 0.793162 Administrative Requirements—Management Systems 0.769594 recipient organization 0.934277 transfer process 0.658996 title 0.525452 international organizations 0.665292 Council 0.528447 new organization 0.642366 individual fellowship 0.65473 Board 0.528424 review 0.526201 statement 0.525862 construction grants 0.679908 successor-in-interest 0.526801	NIH grants 0.781915 additional information 0.652018 IC’s Advisory 0.671293 legal entity 0.680631 Procedures—Property Management 0.646355 approved project period 0.819223 grant funds 0.679599 approval 0.582201 change 0.740921 grant-supported project 0.674314 equipment 0.551691 right 0.525484 foreign institutions 0.665492 administrative responsibility 0.686375 performance 0.531018 recipient’s relinquishment 0.812185 fellow’s department 0.658483	CLICK HERE
17171	National Cancer Institute	Html	es	PC-SPES (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos sobre el uso de PC-SPES como tratamiento del cáncer de próstata. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.	médico herborista 0.418438 Centro Nacional 0.430037 New Hampshire Avenue 0.420405 Drug Administration 0.412734 NCI Best Case 0.437012 datos bibliográficos pubmed 0.422243 siguientes preguntas 0.413766 demostró efectos 0.424258 siguientes riesgos 0.417668 seguro médico 0.412292 múltiples problemas 0.418438 Instituto Nacional 0.517971 acupuntura ayuda 0.412243 Salud Complementaria 0.450225 Visuals Online 0.415643	complementarias revisa 0.422417 Physician Data Query 0.491682 Estados Unidos 0.863449 actúa pc-spes 0.442835 libre uso 0.415953 suficiente cantidad 0.41905 página manejo 0.414584 ¿El tratamiento 0.421322 Nueva York 0.418373 ¿Los beneficios 0.413162 siguientes medicamentos 0.438285 Series Program 0.413051 medicina complementaria 0.925538 diferentes lotes 0.423892	CLICK HERE